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Abstract
Lipoﬁlling or lipografting is a novel and promising treatment method for reduction or prevention of dermal scars after injury.
Ample anecdotal evidence from case reports supports the scar-reducing properties of adipose tissue grafts. However, only a
few properly controlled and designed clinical trials have been conducted thus far on this topic. Also, the underlying mechanism
by which lipoﬁlling improves scar aspect and reduces neuropathic scar pain remains largely undiscovered. Adipose-derived
stromal or stem cells (ADSC) are often described to be responsible for this therapeutic effect of lipoﬁlling. We review the recent
literature and discuss anticipated mechanisms that govern anti-scarring capacity of adipose tissue and its ADSC. Both clinical
and animal studies clearly demonstrated that lipoﬁlling and ADSC inﬂuence processes associated with wound healing, including
extracellular matrix remodelling, angiogenesis and modulation of inﬂammation in dermal scars. However, randomized clinical
trials, providing sufﬁcient level of evidence for lipoﬁlling and/or ADSC as an anti-scarring treatment, are lacking yet warranted
in the near future. © 2017 The Authors Journal of Tissue Engineering and Regenerative Medicine Published by John Wiley &
Sons Ltd
Received 8 February 2016; Revised 16 March 2016; Accepted 14 April 2016
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1. Development of lipoﬁlling procedures
Transfer of adipose tissue, also known as fat grafting,
lipografting or lipoﬁlling, is recognized as a promising
and novel technique for correction of volume deﬁciency,
skin rejuvenation and as treatment for scars. This is
strongly supported by evidence-based clinical trials as
well as fundamental studies in animals and in vitro. The
ﬁrst case of lipoﬁlling in literature dates from 1893, when
Gustav Neuber described the ﬁrst free fat transfer for a
scar that had left a young man with a soft tissue defect
of the face (Neuber, 1893).
As soon as liposuction was further developed in the mid
1980s, also interest developed of re-using the
lipoaspirated subcutaneous adipose tissue. Liposuction
pioneers such as Illouz and co-workers (Illouz, 1983)
developed the ﬁrst clinical applications and methods for
lipoﬁlling to restore or gain volume. The real break-
through in lipoﬁlling came with fat harvesting, subse-
quent processing and subcutaneous administration as
described by Coleman (2002), which allowed better sur-
vival of the lipograft. Centrifugation was the ﬁrst success-
ful attempt to improve fat graft survival by removing oil,
ﬂuid and dead cells from the harvested fat tissue. This
method also inspired clinical trials to assess volumetric
augmentation of the breast and buttocks (Cardenas-
Camarena et al., 2011; Khouri et al., 2012).
Initially, introduced by Coleman in the early 1990s, the
use of small liposuction and lipoﬁlling cannulas also
opened the door for lipoﬁlling of the face and hands for
both reconstructive and aesthetic purposes. Especially in
these applications with rather superﬁcial lipoﬁlling, effects
described as ‘more than volume alone’ were often ob-
served (Coleman, 2002, 2006). This included an improved
appearance and quality of the skin, and has subsequently
been described in many case reports. Yet a mechanistic
underpinning was still lacking. These clinical observations
initiated a wide range of clinical applications for lipoﬁlling
other than just volume adjustment (Rigotti et al., 2007).
This novel idea to use lipoﬁlling for treatment of (the
consequences of) tissue damage has led to the use of
lipoﬁlling to treat burn scars (Klinger et al., 2008) and
even to alleviate scar-associated pain as occurring for
example after mastectomy (Caviggioli et al., 2011).
In 2001, Zuk and colleagues (Zuk et al., 2001) demon-
strated that adipose tissue had a source of endogenous
mesenchymal stem cells (MSC), which were named
adipose-derived stem or stromal cells (ADSC). This dis-
covery signiﬁcantly advanced the use of lipoﬁlling as a
regenerative therapy, as it had been shown that at least
one of the components of adipose tissue had therapeutic
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potential. Since then, many of the beneﬁcial effects ob-
served after lipoﬁlling have been attributed to ADSC.
In this review the authors, both clinicians and biologist,
try to bridge the gap between both worlds, provide a
review of recent literature and summarize the possible
mechanism behind the anti-scarring effect of adipose tis-
sue and its ADSC.
2. Lipoﬁlling on a cellular level
Liposuction simply implicates the harvest of adipose tissue
under negative pressure with small-bore suction cannulas.
By this, the architecture of the fat tissue is disrupted and
small lumps of adipose tissue are harvested and collected
in a sterile environment (bag or collector), which can then
be used for lipoﬁlling subsequently. Inevitably, some
degree of hypoxia occurs around the grafting of the
lipoaspirate. In the recipient, the integration of the graft
requires extensive (re)vascularization, which is primed
by the occurring hypoxia as well as by the pre-existing mi-
crovasculature in the graft. Too large ‘lumps’ of lipograft
obviously develop necrotic cores due to diffusion insufﬁ-
ciency, as a result of which the graft ‘take’ may be reduced
(Dong et al., 2013; Eto et al., 2012; Kato et al., 2014).
Adipocytes are sensitive to hypoxia and as a consequence
prone to apoptosis (Eto et al., 2012; Kato et al., 2014; Suga
et al., 2010). Depending on the technique and time that is
required for harvesting and lipoﬁlling (Fisher et al., 2013;
Pu et al., 2008), 40–90% of the injected lipograft volume
will remain (Hivernaud et al., 2015), while the rest is
resorbed within months after grafting. Oily cysts may
remain in the grafted area as a consequence of this fat
necrosis. To improve fat graft survival, different process-
ing techniques are used (e.g. centrifugation, decantation,
gauze-towel technique). In a systematic review, these
techniques are compared for viability of the fat graft as a
whole (Tuin et al., 2016) in terms of number of viable cells
and in terms of graft volume survival in human and
animal models. For fat graft survival, the gauze-towel
processing technique is found to be superior to
centrifugation or decantation. However, if the focus lies
on the number of ADSC in adipose grafts, centrifugation
improves the number of ADSC that can be isolated, com-
pared with a non-centrifuged fat (Ibatici et al., 2014).
Thus, depending on the goal of lipoﬁlling, different fat-
processing techniques need to be considered carefully.
Adipose tissue, the energy storehouse of the human
body, consists of a parenchymal mass of adipocytes that
is structurally supported by connective tissue and per-
fused by blood vessels. All non-adipocyte tissue is called
stroma or stromal tissue. Adipocytes are the main volu-
metric component of adipose tissue, although they only
comprise up to 20% of all cells (Eto et al., 2009). Adipo-
cytes consist of a thin layer of cytoplasm with an eccentric
nucleus, while most of the volume is made up by the large
central vacuole in which triglycerides predominantly are
stored (Carmen and Victor, 2006).
During development, adipose tissue is derived from the
mesodermal germ layer. The MSC that reside in the meso-
derm differentiate into adipocytes to form adipose tissue.
However, after the embryogenic formation of adipose tis-
sue, some of the MSC or stromal cells remain. In the adult
situation, these MSC are the previously mentioned ADSC.
In the adipose tissue, ADSC reside around the vasculature
(Crisan et al., 2008; Lin et al., 2008; Tang et al., 2008;
Traktuev et al., 2008). Furthermore, ADSC retain the abil-
ity to differentiate into adipocytes, thus functioning as a
source to regenerate adipose tissue (Cawthorn et al., 2012).
3. Lipoﬁlling as a method to treat scars
As stated above, lipoﬁlling is beneﬁcial for skin and scar
treatment. In recent years, a limited number of retrospec-
tive and prospective studies supported previous anecdotal
clinical observations (Table 1a).
3.1. Clinical studies
The clinical efﬁcacy of lipoﬁlling in scar areas is deter-
mined by improvement of the appearance of a scar, such
as size, thickness, stiffness, discoloration of the scar. In
the case of painful scars, this effect can also be measured
by a decrease in pain. In the ﬁrst subsection of this sum-
mary of clinical studies, the focus lies on the ability of
lipografts to improve several of the above-mentioned
appearances of scars, whereas in the second subsection
focus lies on the ability to reduce pain.
3.1.1. Scar appearance
Macroscopically, scars are characterized by a different ap-
pearance to the surrounding skin: discoloration, stiffness
and roughness are features of scarring. In clinical studies,
different outcome measures are used to quantify the de-
gree of scarring on a macroscopic level. The ﬁrst methods
often used to assess scar severity are patient- or observer-
rated grading scales, in which several aspects of scarring
(e.g. colour, stiffness, thickness, irregularity) are rated.
A second method is to use measuring devices for skin elas-
ticity or dermal pigmentation.
The efﬁcacy of lipoﬁlling to improve scar appearance
has been investigated in 16 case reports or clinical trials
(Balkin et al., 2014; Bollero et al., 2014; Bruno et al.,
2013; Coleman, 2006; Guisantes et al., 2012; Klinger
et al., 2008; Maione et al., 2014a; Mazzola et al., 2013;
Pallua et al., 2014; Phulpin et al., 2009; Ribuffo et al.,
2013; Sardesai and Moore, 2007; Wang et al., 2013;
Zellner et al., 2015; Table 1a). In 10 studies of these pub-
lications, comprising of a total of 156 patients, complica-
tions were recorded: in nine of these 10 studies no
complications were recorded, whereas in one study with
12 patients there was a case of cellulitis reported as a
complication. Hence, it seems that risks of lipoﬁlling in
scar areas are rather low. All 14 case reports or clinical
Adipose tissue and ADSC for ﬁbrotic scar treatment 3221






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3222 M. Spiekman et al.









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Adipose tissue and ADSC for ﬁbrotic scar treatment 3223
©2017 The Authors Journal of Tissue Engineering and Regenerative Medicine Published by JohnWiley & Sons Ltd J Tissue Eng Regen Med 2017; 11: 3220–3235.
DOI: 10.1002/term
trials reported some degree of amelioration in scar ap-
pearance after lipoﬁlling: in other words, scars became
less different from normal skin and/or became less visible.
However, the overall result of these clinical studies is not
unequivocal. Firstly, not all studies use the same outcome
measurements to report scar appearance: most studies
used patient satisfaction or patient- and observer-rated
grading scales for scar severity to report the effect of
lipoﬁlling, whereas other studies used measuring devices
for skin elasticity or dermal pigmentation. Secondly,
whether or not there is improvement in scar appearance
varies within these studies: some studies report improve-
ment in most patients, contrasted by no effect in a few
other patients. Lastly, also, within the same study, im-
provement after lipoﬁlling in one outcome measure (e.g.
less stiffness of the scar) is reported, but there is no im-
provement in other outcome measures (e.g. no improve-
ment in discoloration). Thus, the overall trend is that
lipoﬁlling improves scar appearance in several different
outcome measures, which is conﬁrmed by two systematic
reviews (Conde-Green et al., 2016; Negenborn et al.,
2016). However, due to lack of uniformity in intervention
and follow-up, no deﬁnitive conclusions can be drawn.
Only ﬁve well-designed controlled studies had well-
deﬁned objectives and outcome parameters, and had
included both non-treated (Balkin et al., 2014; Ribuffo
et al., 2013; Zellner et al., 2015) or placebo (Bruno
et al., 2013; Maione et al., 2014a) controls. Four of these
studies focused on clinical outcomes (Balkin et al., 2014;
Maione et al., 2014a; Ribuffo et al., 2013; Zellner et al.,
2015) and are discussed below, and one addresses histo-
logical changes (Bruno et al., 2013) and is discussed in
the next section.
In two studies, performed under supervision of the
same senior researcher (Balkin et al., 2014; Zellner et al.,
2015), the effect of lipoﬁlling as adjuvant procedure to
reduce formation of new scars after surgery is evaluated.
During primary cleft lip repair surgery, efﬁcacy of
lipoﬁlling is examined by comparison of pre- and post-
operative pictures for residual cleft stigmata by a blinded
reviewer panel. Compared with primary cleft lip repair
without lipoﬁlling, it resulted in signiﬁcantly less residual
cleft stigmata and thus in better scar appearance.
Apparently lipoﬁlling led to reduction of scar formation.
Also, already existing scars can be treated by means of
lipoﬁlling: in prosthetic breast reconstruction in the set-
ting of post-mastectomy radiotherapy, post-radiotherapy
lipoﬁlling can reduce the degree of capsular contracture
as measured by the Baker classiﬁcation (Ribuffo et al.,
2013). Here, lipoﬁlling apparently is able to prevent or
even (partially) revert the ﬁbrotic process of capsular
contracture. Another example is the treatment of post-
surgical scars in patients with achondroplasia that require
surgical limb lengthening (Maione et al., 2014a). In this
study, lipoﬁlling was compared with saline injection:
lipoﬁlling signiﬁcantly increased skin pliability, and all
but one parameter of the patient and observer scar assess-
ment scale improved. Thus, lipoﬁlling apparently im-
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3.1.2. Pain reduction
Efﬁcacy of lipoﬁlling as a means for pain reduction was
investigated in six case reports or studies (Caviggioli
et al., 2011; Huang et al., 2015a; Klinger et al., 2013;
Maione et al., 2014b; Panettiere et al., 2009; Rigotti
et al., 2007; Ulrich et al., 2012; Table 1b). No complica-
tions were recorded in six of seven studies with a total
of 204 patients; one study did not mention any complica-
tions. All studies reported a signiﬁcant reduction of pain
after treatment of painful scars: only in two of these stud-
ies there was no difference found in one (Rigotti et al.,
2007) and in two (Huang et al., 2015a) patients out of
the entire population. Three studies included control
groups, where lipoﬁlling was compared with no treat-
ment (Caviggioli et al., 2011; Maione et al., 2014b;
Panettiere et al., 2009). Two of these studies, performed
at the same institute, focused on lipoﬁlling as treatment
for neuropathic pain after total mastectomy (Caviggioli
et al., 2011) or breast-conserving surgery (Maione et al.,
2014b). In both studies, it was shown that lipoﬁlling
can reduce pain as measured on a visual analogue scale
by approximately 3 points in the lipoﬁlling group, com-
pared with about 1 point in the control group. The third
study compared results with a representative patient co-
hort: women who have undergone breast reconstruction
and irradiation after mastectomy (Panettiere et al.,
2009). In the lipoﬁlling group there was a signiﬁcant
improvement of all parameters of the LENT-SOMA classi-
ﬁcation (pain, telangiectasias, breast oedema, atrophy
and ﬁbrosis) after treatment. For unknown reasons, the
authors did not compare and analyse the treatment group
with a control group, but they still concluded that
lipoﬁlling leads to pain relief as well as amelioration of
scar appearance.
3.2. Inﬂuence of lipoﬁlling in scars at the tissue level
Microscopically, scars display a loss of rete ridges, seba-
ceous glands and hair follicles. Also, they are character-
ized by increased dermal and epidermal thickness
(Beausang et al., 1998; Ehrlich et al., 1994). The epider-
mal thickening is caused by excessive proliferation of
keratinocytes. In the dermis, the thickening is caused by
excessive extracellular matrix (ECM) production by
myoﬁbroblasts, mainly consisting of collagen type I (van
der Veer et al., 2009). Not only is there an increase in
the amount of collagens, but also in the collagen ﬁbre
thickness, maturation and degree of disorganization
(Beausang et al., 1998; Ehrlich et al., 1994). Even though
there is an increase in the amount of ECM in scarring,
some components of normal skin (e.g. elastin, decorin)
are less abundant in scars (Niessen et al., 1999).
In two patient studies, skin biopsies have been acquired
before and after treatment of scars with lipoﬁlling (Bruno
et al., 2013; Klinger et al., 2008), one study evaluating a
complete series of biopsies from a single patient (Klinger
et al., 2008). After lipoﬁlling, the general structure of
the skin improved, collagen was remodelled and there
was an increase in vascularization.
In a large, placebo-controlled study, lipoﬁlling in large
burn scars was compared with saline injection (Bruno
et al., 2013). In 96 patients, half of the scar was injected
with saline (placebo- or sham-treated group), the other
half was injected with lipoaspirate. Skin biopsies were
taken and analysed after 3 and 6 months. Overall, the his-
tological structure of the scars returned near to that of
normal skin: a better organization and alignment of colla-
gen ﬁbrils, better vascularization of the dermal papillae,
less melanocytic activity in the epidermis and an increase
of the amount of elastin ﬁbres. On cellular level, there was
an increase in cell divisions in the basal layer of the
epidermis and Langerhans cells migrated downwards into
this basal layer. Also, levels of pro-ﬁbrotic factor
transforming growth factor beta 1 (TGF-β1) and pro-
angiogenic factors vascular endothelial growth factor
(VEGF) decreased.
In summary, histological improvement in scar appear-
ance was noted in both studies, expressed as a plethora
of changes on both histological as well as cellular level.
However, why and how lipoﬁlling results in the improve-
ment of all these aforementioned aspects of scarring,
including pain reduction, remains to be elucidated.
3.3. Animal studies
In contrast to clinical studies thus far, experimental ani-
mal models have been able to demonstrate the mecha-
nisms and inﬂuence of lipoﬁlling on dermal scars, scar
exterior and scar pain (Table 2a).
Scar histology has been investigated in two studies
using irradiation skin damage models in rodents (Garza
et al., 2014; Sultan et al., 2011; Table 2a). Skin ﬁbrosis
after radiation in general is a clinically relevant problem,
which can easily be reproduced in rodents. After radia-
tion, dermatitis develops, which eventually gives rise to
ﬁbrotic skin characterized by epidermal thickening and
irregular deposition of collagen in the dermis. Also, com-
pared with normal skin, irradiated skin areas have an
increased vessel density. In two studies in mice, it has
been shown that treatment with lipoﬁlling can reduce
all these hallmark features of radiation-damaged skin
(Garza et al., 2014; Sultan et al., 2011). A decrease in
SMAD3 protein levels, a key protein in the pro-ﬁbrotic
pathway TGF-β/Smad signal transduction pathway, partly
explains the mechanism of scar improvement (Sultan
et al., 2011). In a slightly different model in mice with full
thickness burn wounds, it has been shown that lipoﬁlling
leads to better scar appearance by increasing pro-
angiogenic factors VEGF and stromal cell-derived factor
1 (SDF-1) and decreasing pro-ﬁbrotic factor TGF-β1
(Sultan et al., 2012).
Reduction of neuropathic pain has been reported in
two studies of Huang and co-workers (Huang et al.,
2014, 2015b; Table 2b). Allodynia, painful perception of
a normally non-painful stimulus, after burn wound injury
Adipose tissue and ADSC for ﬁbrotic scar treatment 3225
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was tested in rats by means of behavioural testing. After
burn injury, lipoﬁlling reduced burn-induced allodynia.
On the one hand, lipoﬁlling reduces skin ﬁbrosis and scar-
ring after burn injury (Huang et al., 2014, 2015b) and
lowers expression of pro-inﬂammatory mediators in the
skin (Huang et al., 2015b). On the other hand, lipoﬁlling
induces changes in the spinal cord as well decreases
microglial activation and lessens activation of the pro-
inﬂammatory NFkB signal transduction pathway in spinal
cord cells (Huang et al., 2015b).
It can be concluded that lipoﬁlling in rodent models for
skin injury and ﬁbrosis reduces adverse ﬁbrotic changes.
This appears to be mediated by factors from the lipograft
that can inhibit activation of both ﬁbrotic and inﬂamma-
tory signal transduction pathways. All changes caused by
lipoﬁlling in a dermal scar have been drawn schematically
in Figure 1.
4. Therapeutic mode of action of ADSC
4.1. ADSC: stem or stromal cells?
Because of their ability to differentiate into different cell
types, ADSC are sometimes referred to as adipose stem
cells. However, a true stem cell has the potential to differ-
entiate into other cell types, while maintaining a stable
population of stem cells by the process of self-renewal
(Vogel et al., 1968) with indeﬁnite proliferation capability
due to telomerase activity (Lansdorp, 1995). Embryonic
stem cells are an example of such pluripotent stem cells:
they can undergo an inﬁnite number of cell divisions and
can differentiate into all cell types of the three germ layers
during embryonic development (Thomson et al., 1998).
ADSC, on the other hand, are a type of adult stem cell that
have no telomerase activity and therefore have a limited
Table 2a. Animal studies on lipoﬁlling to improve scar appearance




Radiation of scalp skin
Treatment: lipoﬁlling (human
adipose tissue) 4 weeks
after irradiation.
Control: no lipoﬁlling and/or
no radiation.
Histology of skin for epidermal
thickness (H&E), collagen
arrangement (picrosirius red)
and vessel density (CD31). CT for
fat graft retention. Histology
of fat graft. Assessments 2
and/or 8 weeks after lipoﬁlling.
Return of dermal thickness to
normal level. Decrease in collagen
level to normal level. Increase of
vascular density. All for irradiated
skin treated with lipoﬁlling,
compared with non-treated
irradiated skin. Less fat graft






Full thickness burn wound
on dorsum
Treatment: lipoﬁlling (human
adipose tissue) 2 weeks after
injury.
Control: saline injection
Blood ﬂow measurement by
Laser-Doppler. Photographs.
Histology for collagen arrangement
(picrosirius red) and vessel density
(CD31). Gene and protein
expression analysis of skin.
Assessment 4 and/or 8 weeks after
lipoﬁlling.
Improvement in colour and
texture of wound area. Increased
blood ﬂow in wound area at 4 but
not at 8 weeks. Increase in pro-
angiogenic proteins and
decrease of pro-ﬁbrotic proteins.
Increased vessel density at
4 weeks. Better collagen
alignment at 8 week. All for




Radiation of dorsum skin
Treatment: lipoﬁlling (human
adipose tissue) 4 weeks after
irradiation.
Control: saline injection and/or
no irradiation
Photographs. Histology for
epidermal thickness (H&E), collagen
arrangement (picrosirius red),
vessel density (CD31) and
pro-ﬁbrotic marker (Smad3). All
at 4 and/or 8 weeks after lipoﬁlling.
Decrease in radiation ulcer size
and less hyperpigmentation. Less
epidermal thickening.
Normalization of vascular
density. Decrease in amount of
Smad3 (activation not measured).




Table 2b. Animal studies on lipoﬁlling to reduce pain
Reference Animal model Intervention Follow up Results




adipose tissue) 4 weeks after
injury. Controls: saline
injection or no treatment,
and/or sham burn wound.
Behavioural testing for neuropathic pain:
paw withdrawal test with mechanical
and heat stimuli. Histology of hind paw
skin (H&E, MTC) and of spinal cord
(microglial activation). All at 4 weeks
after lipoﬁlling.
Reduction of burn-induced allodynia. Improvement of
skin histology in burn wound treated with lipoﬁlling:
decrease in collagen deposition, increased cellularity.
Less microglial activation in spinal cord. All observations
for burn wounds treated with lipoﬁlling, compared
with saline injection.




adipose tissue) 4 weeks after
injury. Controls: saline
injection and/or sham burn
wound
Behavioural testing for neuropathic pain:
paw withdrawal tests. Assessment of
inﬂammatory markers in hind paw skin
(COX-2, iNOS, nNOS) and spinal cord
(IL-1β, TNFα, p-IkB and p-NFkB). All at
4 weeks lipoﬁlling.
Reduction of burn-induced allodynia. Decrease of
inﬂammatory markers in hind paw skin and in spinal
cord. Decrease in inﬂammatory pathway activation
(p-IkB and p-NFkB) and in pro-apoptotic pathway
activation (p-JNK) in spinal cord. All for burn wounds
treated with lipoﬁlling, compared with saline injection.
Abbreviations: H&E= haematoxilin and eosin, MTC=Masson’s trichrome, IL-1β= interleukin 1 beta, COX-2 = cyclo-oxygenase 2, TNFα= tumour necrosis factor alpha, CD31 = cluster
of differentiation 31, iNOS = inducible nitric oxide synthase, nNOS = neuronal nitric oxide synthase.
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capacity of proliferation (Mizuno et al., 2012). ADSC can
only differentiate into a limited number of cell types, which
makes them multipotent progenitor cells. Hence, in the
case of ADSC, the authors prefer to speak of adipose-
derived stromal cells instead of adipose-derived stem cells.
4.2. Isolation
Adipose-derived stem or stromal cells can be isolated ei-
ther from intact adipose tissue or from lipoaspirates. The
adipose tissue or lipoaspirate is subjected to enzymatic
digestion using proteases such as collagenase, dispase or
trypsin (Bourin et al., 2013; Pittenger et al., 1999;
Yoshimura et al., 2006; Zuk et al., 2001). After digestion,
the stromal vascular fraction (SVF) that contains ADSC
as well as several other cell types is separated from the
mature adipocytes by differential or density gradient
centrifugation (Bourin et al., 2013; Pittenger et al., 1999;
Yoshimura et al., 2006; Zuk et al., 2001). For cell culture,
the SVF is then seeded into cell culture dishes. Only ADSC
adhere to the tissue culture plastic, whereas other, non-
adherent cell types such as erythrocytes, endothelial cells
and immune cells are removed by washing (Bourin et al.,
2013). Then, the remaining ADSC are culture-expanded
or cryopreserved until further use.
Figure 1. Schematic overview of dermal scar on tissue level, before and after treatment with lipoﬁlling. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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4.3. ADSC in vivo vs. in vitro
Adipose tissue contains two major components: SVF and
adipocytes. SVF is a heterogeneous mix of cells of 11 main
subpopulations based on CD-surface marker expression:
seven adipose-derived populations (CD45) and four
blood-derived populations (CD45pos; Yoshimura et al.,
2006). Three important subpopulations of CD45min cells
are pericytes [in vivo: (CD34pos)/CD34min/CD146pos/
CD31min], supra adventitial cells (in vivo: CD34pos/
CD146min/CD31min) and ADSC (in vivo: CD34pos/
CD90pos/CD31min/CD105low) in a very low number
(Corselli et al., 2012, 2013; Yoshimura et al., 2006;
Zimmerlin et al., 2010). Pericytes and supra-adventitial
cells are both identiﬁed as precursor cells of ADSC, but
there remains controversy (Corselli et al., 2012; Lin
et al., 2008; Traktuev et al., 2008; Zimmerlin et al., 2010).
Enzymatic isolation and culture of those precursor cells
or ADSC results in a large series of cells that can be used
in regenerative medicine. After several days of culture,
the in vivo phenotype of precursor cells changes into an
in vitro speciﬁc phenotype. Most of the cells will lose their
CD34 expression, and almost all of the cells gain expression
of CD105 (Corselli et al., 2012; Yoshimura et al., 2006). The
CD105 marker is also known as endoglin and is a TGF-β
type III receptor, which is expressed on virtually all cells
ofmesenchymal origin, but also on for example endothelial
cells. Ten–20% of the subpopulations remain CD34pos, but
their proliferation rate and adipogenic differentiation
ability is signiﬁcantly lower as compared with the CD34min
subpopulation (Yoshimura et al., 2006; Zimmerlin et al.,
2010). This suggests that 80–90% of the so-called ADSC,
characterized by their phenotype in vitro (CD34min/
CD105pos), are not present in vivo: in other words, the ma-
jority of ADSC acquire their phenotype through culturing.
Culturing of ADSCalso causes dramatic shifts in secretome,
as will be discussed within a few sentences below. The dif-
ferent components and cell types of all fractions of adipose
tissue are summarized in Figure 2.
Some studies have described that regenerative poten-
cies of ADSC are caused by secretion of trophic factors
or differentiation into other cells (Yang et al., 2013). In
vivo, little is known about the secretion of trophic factors
by ADSC. In vitro, secretion of trophic factors by ADSC
in medium (called ADSC conditioned medium) is affected
by many aspects: differences in culture conditions, do-
nors, methods and medium, and cell counts results in dif-
ferent expression of growth factors. For instance, hypoxia
culture upregulates VEGF, platelet-derived growth factor,
placental growth factor and insulin-like growth factor II
(Pawitan, 2014). A 3D culture structure results in thou-
sands of genes with a signiﬁcantly higher mRNA expres-
sion related to ECM, cell adhesion, wound healing and
growth factors as compared with a 2D structure (Amos
et al., 2010). Concentrations of proteins related to angio-
genesis, ECM remodelling and regeneration increase as
well (Amos et al., 2010).
The regenerative potency of SVF might be caused by
the interaction between cells and growth factors. For
example, angiogenesis is signiﬁcantly greater when
pericytes and endothelial cells are combined rather than
the use of pericytes or endothelial cells alone (Traktuev
et al., 2009). Growth factors like VEGF, hepatocyte
growth factor, TGF-β and ECM stimulate angiogenesis
(Rehman et al., 2004). ECM inﬂuences morphogenesis,
and migration speed depends on ECM density during an-
giogenesis (Bauer et al., 2009). Furthermore, ECM func-
tions as a scaffold for other cell types at the site of
injection. The interaction of cellular integrins, i.e. matrix
receptors, suppresses pro-apoptotic signalling. Thus, ap-
plications that include intact, non-enzymatic, generated
SVF might favour graft survival. However, only mechani-
cal isolation of SVF preserves ECM, while enzymatic isola-
tion of SVF disrupts all communicative connections
between cells. As compared with cultured ADSC and
in vitro studied growth factors, freshly isolated SVF con-
tain cells with their in vivo phenotype and growth factor
secretion, respectively. As compared with lipoﬁlling, the
use of SVF might avoid possible complications like cyst
formation or overﬁlling (Agostini et al., 2014), because
only small volumes (less than 10 ml) of SVF are injected.
Thus, because injected volume is limited, there is no risk
of overﬁlling. Because no adipocytes are injected, there
is also no risk of oily cyst formation.
5. ADSC as an anti-scarring treatment
5.1. Clinical studies
To date, the use of ADSC as a cell therapy for treatment for
ﬁbrosis has not been thoroughly investigated in clinical
studies. ADSC have been applied in two non-controlled,
non-randomized studies investigating the effect of ADSC-
enriched lipografts on healing of chronic, intractable
radiation ulcera in 10 patients (Akita et al., 2012) and for
correction of soft tissue defects in 29 patients (Tiryaki
et al., 2011). It was concluded that ADSC improve wound
healing (Akita et al., 2012) and fat graft take (Tiryaki
et al., 2011), and concomitantly decrease deep tissue ﬁbro-
sis and dermal scarring. However, fundamentally, there is
ample evidence for these effects: ADSC increase angiogen-
esis, can induce mitosis in resident tissue cells and are able
to remodel ECM. Based on the design of both studies, no
deﬁnitive conclusions can be drawn on the effectiveness
of the use of ADSC as scar treatment.
On the other hand, studies in the ﬁeld of cell-assisted
lipotransfer (CAL), where lipografts are combined with
ADSC in order to improve fat graft survival, have been sev-
eral properlydesigned, controlled clinical trials (Kolle et al.,
2013;Peltoniemi et al., 2013;Tanikawa et al., 2013) todem-
onstrate the efﬁcacy of CAL for improvement of lipograft
survival over lipoﬁlling alone. In these studies no serious
adverse events were reported after injection of autologous
freshly isolated (Peltoniemi et al., 2013; Tanikawa et al.,
2013) or culture expanded (Kolle et al., 2013) ADSC. It
can be concluded that use of autologous ADSC in patients
is safe. These clinical trials warrant the dissection of the
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underlying mechanism via animal models and in vitro
investigations of underlying molecular pathways.
5.2. Animal studies
In animal wound-healing models, where ADSC were used
to speed up wound healing (Lam et al., 2013; Lee et al.,
2011; Uysal et al., 2014; Zonari et al., 2015), it was ob-
served that ADSC reduce severity of scarring after wound
closure (Table 5). ADSC improved the wound healing rate
in three out of four studies, and smaller ﬁbrotic areas
remained after wound healing (Lam et al., 2013). Yet,
the epidermal thickness increased (Uysal et al., 2014;
Zonari et al., 2015), and the gene expression of the
pro-ﬁbrotic markers α-smooth muscle actin and TGF-β1
Figure 2. Summary of different fractions of adipose tissue before, during and after mechanical or enzymatic isolation of adipose-derived stem or stromal cells (ADSC). Cell types
and their cell surface markers are represented for all different fractions. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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decreased (Uysal et al., 2014; Zonari et al., 2015) while
the gene expression of anti-ﬁbrotic ﬁbroblast growth
factor and pro-angiogenic VEGF (Uysal et al., 2014)
increased. Together, this indicates that in vivo
administered ADSC suppress the formation of dermal
scar, through augmented wound healing. The comparison
with clinical treatment of pre-existing scars is hampered,
because these animal studies more prevent scar formation
than revert pre-existing scars.
In animal models speciﬁcally designed to study scar-
ring (Yun et al., 2012; Zhang et al., 2015) and to study
the ﬁbrotic disorder of Peyronie’s disease (Castiglione
et al., 2013; Table 5), it was noted that deposition of
ECM components, such as collagen type I and III and
elastin, was decreased after treatment of scars with
ADSC. Also, collagen ﬁbre alignment improved in the
treated scar areas (Yun et al., 2012; Zhang et al.,
2015). Functionally, treatment of scars with ADSC leads
to smaller scars (Yun et al., 2012) and less scar
elevation (Yun et al., 2012). Together, we surmise that
the remodelling of the ﬁbrotic matrix in a scar by ADSC
is one of the components that governs scar reduction.
Interestingly, ADSC are derived from connective tissue
(SVF of fat), but appear to act as ‘good guys’ in contrast
to the scar myoﬁbroblasts, which are connective tissue
cells too, but ‘bad guys’. The ADSC are capable of tilting
the balance between ECM deposition and ECM
degradation in favour of degradation. Whether this
depends solely on matrix inﬂuence or also on direct
inﬂuence on the scar-resident myoﬁbroblast remains to
be investigated.
In conclusion, treatment of wounds or mature scars
with ADSC in different animal models has shown to result
in faster wound healing and reduction of scar tissue on
both macroscopic and microscopic levels. Thus, the use
of autologous ADSC to improve wound healing and to
prevent or diminish scar tissue in patients seems to be a
very exciting and promising way to go.
Table 5. Animal studies on ADSC as a treatment for wound healing and scar prevention or reduction













the penis. Erectile function
measurements 5 weeks after
ADSC-treatment.
Decrease in collagen III and elastin
deposition (immunoﬂuorescence).
Improved erectile function.
Both in ADSC-treated vs. control
group.






mouse ADSC on SIS
patch Control: patch alone or
Topical application of ADSC
Wound healing speed, ﬁbrosis
(H&E and MTC staining) after
wound healing. Measured at day
14 after wounding.
Wound healing improved slightly
with ADSC on SIS. Decreased
ﬁbrotic area with topical ADCS
and with ADSC on SIS Both
compared ADSC on SIS with
untreated or SIS alone.
Lee et al. (2011) Nude mouseSplinted
excisional wound healing
model
Collagen gel 1 × 10
6
human ADSC in collagen
gel Control: human dermal
ﬁbroblast
in collagen gel, or collagen gel
alone
Photographs of wound area size
10 days after wounding. Scar size
28 days after wounding (H&E
staining).
ADSC collagen gel group had a
faster wound closure rate than
control, but slower than DF
collagen gels. Scar size increased
in ADSC and DF collagen gel
groups compared with control
(based on H&E staining alone).
Uysal et al. (2014) RatFull thickness
excisional
wound
No 1 × 10
7
labelled rat ADSC








SMA, FGF, VEGF, TGF-β1, β2 and
β3. All at day 56 after wounding.
Increased wound healing speed,
neovascularization and epithelial
thickness. Lower αSMA, TGF-β1, β2
and β3 and higher FGF and VEGF
expression. All outcomes for ADSC
and BMSC treated groups vs.
control group
Yun et al. (2012) PigScarring model, after
full thickness wound




Three consecutive local injections
Area, colour and ﬂexibility of scar.
Histological assessment of
collagen arrangement (MTC),
number of mast cells. Gene
expression analysis of scar tissue.
All until 50 days after ADSC
injection.
Slightly smaller scar area and
slightly higher pliability. Higher
amount of mature collagen. Lower
mast cell count. Lower gene
expression of αSMA and TIMP1,
higher expression of MMP1. All
outcomes for ADSC treated group
vs. control group.
Zhang et al. (2015) RabbitHypertrophic scar
model, after full thickness
wound
No 4 × 10
6
labelled rabbit ADSC
Control: ADSC CM, culture
medium, or untreated. Local
injection
Histology for scar size and
collagen arrangement (H&E and
MTC). Gene expression analysis of
scar tissue.
All until 35 days after ADSC
injection.
Less scar elevation. Less deposition
and better alignment of collagen.
Lower gene expression of αSMA
and collagen I. All outcomes for
ADSC or ADSC CM treated groups
vs. culture medium or untreated
groups.
Zonari et al. (2015) RatFull thickness
excisional
wound
PHBV scaffold 1 × 10
6
labelled rat ADSC in
PHBV scaffoldControl: PHBV
scaffold or untreated
Wound healing speed, skin
thickness (H&E), vessel density,
collagen arrangement (MTC) and
gene expression analysis. All until
28 days after wounding.
No difference in wound-healing
speed. Improved skin thickness
and collagen ﬁbre organization.
Lower αSMA and TGF-β1, higher
TGF-β3 gene expression. No
difference in vessel density at
28 days. All these outcomes for
ADSC in scaffold vs. scaffold alone.
Abbreviations: ADSC = adipose-derived stem/stromal cell, SIS = small intestinal submucosa, H&E = haematoxillin and eosin, MTC =Masson’s trichrome, DF = dermal ﬁbroblast, αSMA
= alpha smooth muscle actin, FGF = ﬁbroblast growth factor, VEGF = vascular endothelial growth factor, TGF-β = transforming growth factor beta, BMSC = bone marrow mesen-
chymal stem/stromal cell, PBS = phosphate-buffered saline, TIMP1 = tissue inhibitor of metalloproteinase, MMP = matrix metalloproteinase, ADSC CM = ADSC conditioned medium,
PHBV = polyhydroxybutyrate-co-hydroxyvalerate.
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Figure 3. Harnessing the power of fat for ﬁbrotic scar treatment: as whole adipose tissue in lipoﬁlling, or in loose components such as stromal vascular fraction (SVF), adipose-
derived stem or stromal cells (ADSC) or ADSC conditioned medium. As listed, we propose each form has its own ideal application. [Colour ﬁgure can be viewed at
wileyonlinelibrary.com]
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5.3. In vitro studies
Myoﬁbroblasts play a major role in wound healing and
scarring: activated myoﬁbroblasts proliferate, produce
ECM-like collagens and have the ability to contract. After
wound healing, myoﬁbroblasts normally are resolved via
apoptosis. However, if myoﬁbroblasts persist, scarring will
be the end result (Klingberg et al., 2013). In two in vitro
studies, it has been shown that trophic factors, produced
by ADSC, can inhibit the myoﬁbroblast phenotype of
dermal ﬁbroblasts after stimulation with the pro-ﬁbrotic
cytokine TGF-β1 (Spiekman et al., 2014) and can inhibit
that of ﬁbroblasts derived from Dupuytren’s nodules
(Verhoekx et al., 2013). Proliferation, ECM production
and contraction of these ﬁbroblasts were reduced, which
indicates that growth factors and cytokines of ADSC have
the ability to prevent or even to reverse dermal scarring.
6. Future perspectives
As discussed throughout, harnessing the power of fat for
ﬁbrotic scar treatment is an emerging concept in regener-
ative medicine. Fat can, however, be used in several
fashions: as whole adipose tissue in lipoﬁlling, or in loose
components such as SVF, ADSC or even ADSC conditioned
medium. In our opinion, each of these forms has its own
ideal application in regenerative medicine (Figure 3).
The use of whole adipose tissue in lipoﬁlling is optimal
when there is a soft tissue defect that needs ﬁlling. Be-
sides the ‘volumizing’ effect, scar reduction is a beneﬁcent
side-effect of this treatment. Though, when extra volume
is not a requirement or even a contraindication, the use of
SVF offers an excellent alternative. In the setting of
ﬁbrotic dermal scars in areas where addition of extra
volume is not aesthetically desirable, SVF is a good
alternative for whole adipose tissue. Besides for use in
dermal ﬁbrotic scars, use of SVF opens the door for other
clinical applications. Whole adipose tissue is not ﬁt for use
in ﬁbrotic disorders in organs, such as cardiac or liver
ﬁbrosis. SVF, however, would be a suitable alternative to
combat organ ﬁbrosis. SVF has all the requirements to
act as a scaffold for repair, as it contains ready-to-use mi-
crovasculature, ECM and ADSC to orchestrate the repair
process. For example, acceleration of wound healing or
alteration of early scar formation would be exemplary
candidates for use of SVF. Nonetheless, in case of pre-
existing scars, a more rigorous remodelling of the mature
scar tissue is necessary. Here, the microvasculature and
ECM components of SVF are not a prerequisite. Thus,
the application of ADSC would sufﬁce. ADSC could
orchestrate the remodelling, for example by
immunomodulation or by instruction of the resident
tissue cells from a synthetic to a proteolytic or a non-
contractile phenotype. Last but not least, ADSC condi-
tioned medium offers the ultimate solution when only in-
structive (growth) factors are required. In this way, use of
allogeneic cells or xenogenic cell culture products can be
circumvented, resulting in an off-the-shelf product. ADSC
conditioned medium would be ideal for topical applica-
tion or injection in wounds or developing scars.
7. Conclusion
Since Neuber’s ﬁrst report in 1893, the use of adipose tis-
sue has gradually developed into an exciting new way to
be used in the treatment and prevention of scar tissue. Af-
ter lipoﬁlling or after application of ADSC, improvement
of scar appearance or reduction in scar-related pain has
been reported in many case reports and clinical studies.
Lipoﬁlling and ADSC seem promising to lessen the sever-
ity of developing as well as pre-existent ﬁbrotic scarring.
A factor that complicates deﬁnitive conclusions in the efﬁ-
cacy of lipoﬁlling and ADSC is the wide variety in experi-
mental design of the studies. Each study uses different
outcome measurements, at different time points in pre-
existent as well as in developing scarring. Up to date,
large randomized controlled clinical trials using
lipoﬁlling, ADSC, SVF or ADSC conditioned medium for ﬁ-
brotic scar treatment are still lacking. For future random-
ized controlled clinical trials, we recommend researchers
to carefully select their source of stromal cells depending
on their goal.
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